Blog

Plumbers, electricians and welders will be in huge demand as part of a national plan to train people for an extra 400,000 green jobs in the next five years, Ed Miliband has said.

The energy secretary revealed a new scheme to double those working in green industries by 2030, with a particular focus on training those coming from fossil fuel jobs, school leavers, the unemployed, veterans and ex-offenders.

He said the plan would involve measures to ensure companies receiving public grants and contracts need to create good jobs across the clean energy sector. It will also promote greater trade union recognition and collective bargaining in the clean energy sector, including when jobs are offshore.

Miliband’s announcement was welcomed by unions from Unite to the GMB, which have long been pushing for a more detailed plan for how people will switch from old fossil fuel industries to those in clean energy in the future.

As part of the plan, 31 professions will be designated as priorities for recruitment and training, with plumbers, heating and ventilating installers at the top of the list with an additional 8,000 to 10,000 needed by 2030. Carpenters, electricians and welders are the next highest in demand on the list, with 4,000 to 8,500 extra of each required.

Miliband said the national plan “answers a key question about where the good jobs of the future will come from”.

As well as flagging to jobseekers what kind of green jobs are needed, the energy secretary said it would “send a signal to the mayors, regional mayors, who have lots of responsibilities in this area about where they need to be directing their further education colleges and others where the big opportunities are.

“It sends a signal to industry, who have been saying … set out what are the needs going be and how are we going to fill them.”

Miliband said the promise of hundreds of thousands of new roles in the renewables and clean energy sector would show that Reform UK is “waging war on jobs” by challenging the switch to net zero.

“Obviously, this is a massive fight with Reform,” he said. “Reformers said they’ll wage war on clean energy. Well, that’s waging war on these jobs … It’s all part of their attempt at a culture war, but I actually think they’re out of tune with the British people because I think people recognise that we need, that we want the jobs from clean energy.

“We want the lower bills that it can bring. So let’s have the argument as a country about what we’re going to do. I’m really confident we can win this argument.”

He said estimates show jobs in wind, nuclear, and electricity networks all advertise average salaries of more than £50,000, compared with the UK average of £37,000, and are spread across coastal and post-industrial communities.

Other announcements in the plan include five new technical excellence colleges that will help train young people into essential roles, with skills pilots in Cheshire, Lincolnshire and Pembrokeshire to be backed by £2.5m towards new training centres, courses or career advisers.

skip past newsletter promotion

after newsletter promotion

There will also be a new programme to match veterans up with careers in solar panel installation, wind turbine factories and nuclear power stations, with other tailored schemes for ex-offenders, school leavers and the unemployed.

Government research suggests that 13,700 people who were out of work possessed many of the skills required for key roles in the clean energy sector, such as engineering and skilled trades.

There will also be a focus on upskilling existing oil and gas workers, who will benefit from up to £20m in total from the UK and Scottish governments to provide bespoke careers training for thousands of new roles in clean energy.

Sharon Graham, Unite’s general secretary, said: “Well paid, secure work must be at the heart of any green transition. Unite members will welcome the commitment to 400,000 green jobs with strong collective bargaining rights. The actions set out in this plan are initial steps in what must be an ambitious strategy for tangible jobs, backed by an equally ambitious programme of public investment.”

Charlotte Brumpton-Childs, a national officer at the GMB, said: “GMB has long campaigned for a jobs-first transition. The government is listening and having a jobs plan to underpin the industrial strategy is exactly what this country needs.”

Drug resistance remains one of the greatest challenges in the treatment of advanced lung cancer, particularly in patients with tumors harboring monogenic alterations. Despite significant progress in targeted therapies, resistance ultimately limits the effectiveness of treatment, underscoring the need for new strategies to overcome both intrinsic and acquired resistance mechanisms.

At the European Society for Medical Oncology 2025 Congress in Berlin, Germany, Pasi A. Jänne, MD, senior vice president for Translational Medicine and David M. Livingston, MD chair at Dana-Farber Cancer Institute, a professor of medicine at Harvard Medical School, discussed the underlying mechanisms of resistance, how to prevent resistance, and the role of antibody drug conjugates (ADCs) in overcoming barriers to optimal treatment response.

Understanding the Origins of Resistance

Resistance in lung cancer arises primarily through 2 mechanisms: pre-existing resistant clones and drug tolerance states. Pre-existing clones are subpopulations of tumor cells that harbor inherent resistance mechanisms before therapy begins. In contrast, the drug tolerance state emerges when tumor cells survive initial targeted therapy, entering a reversible, persistent state. These cells maintain some sensitivity to therapy but can eventually acquire multiple resistance mechanisms over time.

Targeted therapy resistance is highly heterogeneous. In individual patients, multiple resistance pathways may develop simultaneously, including secondary mutations, bypass signaling pathways, and histologic transformation. For example, EGFR-mutant lung cancers can develop compound mutations, downstream pathway activation, or transform into small cell or squamous histology, each representing a distinct resistance mechanism. This complexity makes designing effective treatment strategies particularly challenging.

“”Cancer is heterogeneous, and multiple resistance mechanisms can develop simultaneously,” explained Jänne, “which makes it challenging to determine the best therapeutic strategy.”

Preventing Resistance Through Combination Therapies and Advanced Inhibitors

One approach to managing resistance is the development of more potent inhibitors capable of overcoming resistance to earlier-generation drugs. For instance, osimertinib (Tagrisso; AstraZeneca) was designed to inhibit EGFR T790M mutations, while lorlatinib (Lorbrena; Pfizer Inc) targets resistance mutations arising after prior-generation ALK inhibitors.

Combination therapy also plays a critical role. Clinical studies have shown that pairing targeted inhibitors with additional agents can improve response rates and delay the emergence of resistance. In EGFR-mutant lung cancer, trials combining osimertinib with MET inhibitors—such as capmatinib (Tabrecta; Novartis Pharmaceuticals Corporation) or savolitinib (Orpathys; HUTCHMED; AstraZeneca)—demonstrated higher response rates in patients with MET amplification or high MET expression. These biomarker-driven approaches illustrate the potential of combination strategies to preemptively circumvent specific resistance pathways.

Targeting Drug-Tolerant, Persistent Cancer

A challenging subset of lung cancer involves drug-tolerant, persistent tumor cells. These cells survive initial targeted therapy, often displaying stem cell-like properties, slow cycling, epithelial-mesenchymal transition (EMT) characteristics, and epigenetic modulation. Local therapies, such as consolidated radiation to residual lesions, have shown potential controlling these populations. Small studies demonstrate improved progression-free survival (PFS) and overall survival (OS) when radiation is combined with ongoing targeted therapy.

“This drug-tolerant persistent state represents a therapeutic opportunity,” said Jänne. “If we can eliminate this intermediate population [cells that survive therapy but aren’t fully resistant], we may extend the benefit of first-line targeted therapy and delay resistance.”

Preclinical models have further illustrated the potential of targeting this drug-tolerant state. In a mouse model of EGFR-mutant lung cancer, chimeric antigen receptor (CAR) T-cell therapy cured 4 out of 10 mice with durable responses, whereas treatment with osimertinib alone or with ADCs failed to produce long-term cures. These findings suggest that novel systemic therapies, including cellular therapies, may effectively eliminate residual resistant populations and extend the duration of benefit from first-line targeted therapy.

Addressing Acquired Resistance

Acquired resistance occurs when tumors initially respond to therapy but later progress. The pattern of progression—whether systemic or focal—guides subsequent treatment decisions. For localized progression, clinicians may employ targeted local therapies such as radiation, while continuing systemic targeted therapy. For systemic progression, tissue biopsies, often combined with liquid biopsies, provide critical insights into the mechanisms of resistance, which can then inform tailored treatment approaches.

For example, EGFR-mutant tumors that acquire MET amplification can respond to combination therapy with osimertinib and MET inhibitors, showing response rates up to 58% compared with 34% for chemotherapy. Similarly, resistance mechanisms involving RET or ALK rearrangements can be addressed with combination strategies targeting the specific alterations. However, the heterogeneity of resistance mechanisms in individual tumors means that a single approach rarely addresses all pathways simultaneously.

Small Cell Transformation and Novel Therapeutics

Another mechanism of resistance in EGFR-mutant NSCLC is transformation into small cell lung cancer (SCLC). These transformed tumors are treated according to standard SCLC protocols, typically platinum-etoposide chemotherapy. Novel approaches, including tarlatamab (Imdelltra; Amgen) and ADCs, are being evaluated for efficacy in transformed SCLC. Early evidence suggests that combining targeted therapy with chemotherapy may enhance responses in this context, and ongoing trials will clarify the role of immune checkpoint inhibitors and ADCs in these transformed tumors.

The Role of ADCs and Broader Therapeutic Approaches

ADCs are emerging as a promising therapeutic option in resistant lung cancers, including those with EGFR mutations. ADCs can target a broad range of resistance mechanisms independent of the specific mutation, providing a more universal approach for patients lacking identifiable targetable alterations. For example, data from trials of troponin-2 ADCs and datopotamab deruxtecan-dlnk (Datroway;_Daiichi Sankyo, Inc) show response rates of approximately 40% in EGFR-mutant lung cancer, with some durable responses. These agents offer hope for patients whose tumors exhibit complex or polyclonal resistance mechanisms.

The Need for Biomarkers

Despite these advances, a major limitation in treating resistant lung cancers is the lack of predictive biomarkers. Biomarkers are essential for identifying which patients are most likely to benefit from combination therapy, local interventions, ADCs, or novel cellular approaches. Ongoing research aims to discover robust markers to guide treatment decisions and maximize therapeutic benefit while minimizing unnecessary toxicity.

“Careful biomarker-driven strategies will be key to tailoring treatments and improving patient outcomes in resistant lung cancers,” Jänne said.

Conclusion

Drug resistance remains a formidable challenge in advanced lung cancer, but evolving strategies offer new hope. By understanding the origins of resistance—from pre-existing clones to drug-tolerant persistent states—clinicians can better tailor therapy to individual patients. Combination therapies, local interventions, ADCs, and CAR T cells all provide promising avenues to overcome resistance, while ongoing research into biomarkers will be crucial for guiding these approaches.

REFERENCES

Wolf J, Jänne P, Leighl N. Targeting oncogenes in NSCLC. Presented at: European Society for Medical Oncology 2025 Congress. October 17, 2025, to October 21, 2025. Berlin, Germany.